Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir XR in healthy subjects
NCT03239353Phase 1Completed
- Sponsor
- Aucta Pharmaceuticals, Inc.
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of entecavir in hepatitis B (HBV) (5 arms), sponsored by Aucta Pharmaceuticals, Inc. Primary endpoint: Pharmacokinetics of ETV XR at 22 days. Started Oct 2017; status: completed.
02
Drugs
entecavir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03239353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239353.